• Markets
    • icon
  • Companies
RNO · ASX

Rhinomed Limited (ASX:RNO)

AU$0.04

 0.0 (0.0%)
ASX:Live
01/12/2023 10:55:40 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RNO Overview

RNO Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About RNO

Website

Rhinomed Limited

Telephone

61.3.8416.0900

Address

Level 1 132 Gwynne Street Cremorne, Victoria (VIC) 3121

Description

Rhinomed Ltd. is medical technology company, which engages in the identification, acquisition, and commercialization of stage therapeutic delivery technologies. It operates through Turbine, Mute and Pronto technology. The Turbine technology, a nasal dilator designed to assist breathe during aerobic exercise. The Mute technology, a nasal technology that is designed to improve sleep by breathing more and snoring less. The Pronto technology is a Vapor Inhaler, which opens the nose to improve airflow and delivers the soothing vapors from essential oils. The company was founded on February 9, 2004 and is headquartered in Cremorne, Australia.

RNO Price Chart

Key Stats

Market Cap

AU$11.43M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.12

Trade Value (12mth)

AU$1,157.00

1 week

17.65%

1 month

14.29%

YTD

-65.22%

1 year

-65.22%

All time high

6.15826

Key Fundamentals

EPS 3 yr Growth

-13.200%

EBITDA Margin

-121.70%

Operating Cashflow

-$7m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-29.10

Quick Ratio

0.20

Other Data

Shares on Issue (Fully Dilluted)

286m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RNO Announcements

Latest Announcements

Date Announcements

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 18

Investor Presentation

×

Investor Presentation

31 October 07

Annual Report to shareholders

×

Annual Report to shareholders

31 March 23

Change in substantial holding WG

×

Change in substantial holding WG

31 March 15

Rhinomed to Present at Master Investor UK Show

×

Rhinomed to Present at Master Investor UK Show

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Preliminary Final Report

×

Preliminary Final Report

31 August 22

Preliminary Final Report

×

Preliminary Final Report

30 September 22

Final Director's Interest Notice EK

×

Final Director's Interest Notice EK

30 September 15

Annual Report to shareholders

×

Annual Report to shareholders

30 November 15

2015 Annual General Meeting - Chairman's Address

×

2015 Annual General Meeting - Chairman's Address

30 November 15

2015 Annual General Meeting - CEO Presentation

×

2015 Annual General Meeting - CEO Presentation

30 November 15

Results of 2015 Annual General Meeting

×

Results of 2015 Annual General Meeting

30 November 12

Consegna Group Limited - CTO Presentation (CGP-AU)

×

Consegna Group Limited - CTO Presentation (CGP-AU)

30 March 11

Helicon Group Limited - Conference Presentation on Vibrovein (HCG-AU)

×

Helicon Group Limited - Conference Presentation on Vibrovein (HCG-AU)

30 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 September 23

Rhinomed Ltd Audited Financial Report FY23

×

Rhinomed Ltd Audited Financial Report FY23

29 September 14

Annual Report to shareholders

×

Annual Report to shareholders

29 September 14

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 October 14

Company Presentation

×

Company Presentation

29 October 12

Consegna Group Limited - Annual Report to shareholders (CGP-AU)

×

Consegna Group Limited - Annual Report to shareholders (CGP-AU)

29 October 12

Consegna Group Limited - Notice of Annual General Meeting/Proxy Form (CGP-AU)

×

Consegna Group Limited - Notice of Annual General Meeting/Proxy Form (CGP-AU)

29 November 19

Rhinomed AGM Presentation

×

Rhinomed AGM Presentation

29 July 16

Rhinomed's 2016 Bioshares Conference Presentation

×

Rhinomed's 2016 Bioshares Conference Presentation

28 September 22

Rhinomed Limited Audited Financial Report FY22

×

Rhinomed Limited Audited Financial Report FY22

28 November 07

AGM Presentation to Shareholders

×

AGM Presentation to Shareholders

28 July 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

RNO Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.02 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.02 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.2 40.2 -89.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.02 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.7 18.6 -46.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -13.7 -22.0 -36.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.02 -0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -69.4 11.8 -302.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 256 262 286 Lock Lock Lock
Basic m Lock Lock Lock Lock 256 262 286 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 4 9 7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.2 133.8 -17.9 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 8 8 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -3 2 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.5 152.5 -111.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -79.2 17.8 -2.5 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 179 82 103 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -5 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.5 34.9 -69.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -211.7 -59.0 -121.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -6 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.5 31.3 -64.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -226.9 -66.7 -133.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -6 -11 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -5 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -18.9 38.9 -106.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -221.8 -58.0 -146.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -6 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 6 5 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -7 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.4 -23.0 -9.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.4 -0.7 -1.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 2 0 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 7 8 3 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -2 6 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 3 9 Lock Lock Lock
Equity $m Lock Lock Lock Lock 5 5 -6 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 5 5 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.0 2.3 -222.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -131.9 -62.1 -354.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -181.3 -104.9 170.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -106.0 -114.4 -404.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -105.2 -102.3 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -64.9 -111.3 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -201.9 -121.3 -29.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.2 0.3 -0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -39.2 -32.7 -90.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.7 1.7 0.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.6 1.3 0.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 62.4 35.9 7.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -385.7 -179.8 -76.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 3.7 5.6 4.2 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 20.0 10.7 8.2 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.6 3.9 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 18.4 19.8 22.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.6 1.1 2.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.6 1.1 2.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -232.7 -63.5 -153.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -138.4 -68.0 -372.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -131.9 -62.1 -354.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.7 -0.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -181.3 -104.9 170.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -181.3 -104.9 170.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 18.2 34.1 44.6 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 97.4 64.7 87.7 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 115.6 98.8 132.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 28.5 53.7 91.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 87.1 45.1 41.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RNO Shortsell

Frequently Asked Questions

The current share price of Rhinomed Limited (RNO:ASX) is AU$0.04.
The 52-week high share price for Rhinomed Limited (RNO:ASX) is AU$0.12.
The 52-week low share price for Rhinomed Limited (RNO:ASX)? is AU$0.03.
Rhinomed Limited (RNO:ASX) does not pay a dividend.
Rhinomed Limited (RNO:ASX) does not pay a dividend.
Rhinomed Limited (RNO:ASX) has a franking level of 0%.
Rhinomed Limited (RNO:ASX) is classified in the Healthcare.
The current P/E ratio for Rhinomed Limited (RNO:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.